Article
Oncology
Angela Barillaro, Mara Caroprese, Laura Cella, Anna Viggiano, Francesca Buccelli, Chiara Daponte, Chiara Feoli, Caterina Oliviero, Stefania Clemente, Antonio Farella, Manuel Conson, Roberto Pacelli
Summary: Brain metastases are severe events in patients with solid tumors. Stereotactic radiation therapy is an effective treatment for brain metastases, but it may lead to radiation necrosis, which can impact patient's quality of life. Prompt recognition and treatment are necessary for managing radiation necrosis.
Article
Oncology
Alan C. Hartford, Gobind S. Gill, Divya Ravi, Tor D. Tosteson, Zhongze Li, Gregory Russo, Clifford J. Eskey, Lesley A. Jarvis, Nathan E. Simmons, Linton T. Evans, Benjamin B. Williams, David J. Gladstone, David W. Roberts, Jay C. Buckey
Summary: The study evaluated the feasibility, safety, and response of administering hyperbaric oxygen (HBO) prior to stereotactic radiosurgery (SRS) for brain metastases. The results showed that adding HBO to SRS did not result in a decrement in radiation necrosis and other clinical outcomes.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Da Hyun Lee, Ji Eun Park, NakYoung Kim, Seo Young Park, Young-Hoon Kim, Young Hyun Cho, Ho Sung Kim
Summary: The study showed that solid low-enhancing and nonviable tissue habitats on structural MRI can help localize viable tumors in patients with brain metastases after SRS. Physiologic MRI habitats were not indicative of viable tumors. These findings suggest that structural MRI may be more useful in distinguishing viable tumor from radiation necrosis.
EUROPEAN RADIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Paola Anna Jablonska, Nuria Galan, Jennifer Barranco, Sergio Leon, Ramon Robledano, Jose Ignacio Echeveste, Alfonso Calvo, Javier Aristu, Diego Serrano
Summary: This study investigates the role of STAT3 and other inflammatory markers in the development of brain radiation necrosis (RN). The results suggest that STAT3 plays an important role in RN development, and targeting STAT3 may be a promising strategy for ameliorating symptomatic RN in brain metastases patients undergoing stereotactic radiosurgery (SRS).
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Clinical Neurology
Penny K. Sneed, Jason W. Chan, Lijun Ma, Steve E. Braunstein, Philip Theodosopoulos, Shannon E. Fogh, Jean L. Nakamura, Lauren Boreta, David R. Raleigh, Benjamin P. Ziemer, Olivier Morin, Shawn L. Hervey-Jumper, Michael W. McDermott
Summary: This study evaluates the risk and time course of adverse radiation effects (AREs) in patients with brain metastases previously treated with stereotactic radiosurgery (SRS) and salvage SRS. The authors found that repeat single-fraction SRS had good outcomes for brain metastases <= 2 cm, with a low risk of symptomatic AREs.
JOURNAL OF NEUROSURGERY
(2023)
Article
Oncology
Laure Kuntz, Clara Le Fevre, Delphine Jarnet, Audrey Keller, Philippe Meyer, Christophe Mazzara, Helene Cebula, Georges Noel, Delphine Antoni
Summary: This retrospective study analyzed the data of patients who received at least two courses of SRT between 2010 and 2020. The results showed that NDFS and OS after SRT were influenced by various factors, including the number of treatments, patient condition, salvage WBRT, and metastasis velocity.
Article
Oncology
Jinghui Pan, Jinsheng Xiao, Changli Ruan, Qibin Song, Lei Shi, Fengjiao Zhuo, Hao Jiang, Xiangpan Li
Summary: Despite promising results shown by deep learning in automated radiotherapy planning, its application to a specific scenario of stereotactic radiosurgery (SRS) for brain metastases using fixed-field intensity modulated radiation therapy (IMRT) on a linear accelerator remains limited. This study aimed to develop and verify a deep learning-guided automated planning protocol tailored for this scenario, which successfully achieved the goal. By using 70 SRS plans for solitary brain metastases, a deep learning-guided automated planning process was established, including steps such as clinical dose prediction facilitated by deep-learning algorithms.
FRONTIERS IN ONCOLOGY
(2023)
Review
Surgery
Eric J. J. Lehrer, Roman O. O. Kowalchuk, Henry Ruiz-Garcia, Kenneth W. W. Merrell, Paul D. D. Brown, Joshua D. D. Palmer, Stuart H. H. Burri, Jason P. P. Sheehan, Alfredo Quninoes-Hinojosa, Daniel M. M. Trifiletti
Summary: Stereotactic radiosurgery (SRS) is an effective and safe treatment method for intracranial neoplasms and functional disorders. It has shown favorable rates of tumor control and cognitive preservation for brain metastases, but also carries risks of local failure and complications. Further research is needed to explore its potential benefits for high grade gliomas.
FRONTIERS IN SURGERY
(2022)
Article
Oncology
J. A. Crouzen, A. L. Petoukhova, M. L. D. Broekman, M. Fiocco, U. J. Fisscher, J. H. Franssen, C. G. M. Gadellaa-van Hooijdonk, M. Kerkhof, M. Kiderlen, M. E. Mast, C. M. van Rij, R. Nandoe Tewarie, M. A. E. van de Sande, P. P. G. van der Toorn, R. Vlasman, M. J. Vos, N. C. M. G. van der Voort van Zyp, R. G. J. Wiggenraad, L. M. Wiltink, J. D. Zindler
Summary: A multicenter prospective randomized study aims to compare the incidence of adverse local events in patients with brain metastases using fractionated stereotactic radiosurgery (fSRS) versus stereotactic radiosurgery (SRS) in one or three fractions. The study aims to reduce the risk of radionecrosis and improve the effectiveness of brain metastases treatment.
Article
Biology
Leonie Johannwerner, Elisa M. Werner, Oliver Blanck, Stefan Janssen, Florian Cremers, Nathan Y. Yu, Dirk Rades
Summary: Based on the study, a maximum biologically effective dose (BED) of 45 Gy(12) is recommended for stereotactic radiosurgery (SRS) of brain metastases measuring 21-30 mm. However, for de novo lesions without prior brain irradiation, the tolerable BED may be higher than 45 Gy(12). This study investigated the occurrence of radiation necrosis (RN) after single-fraction SRS or fractionated stereotactic radiotherapy (FSRT) with a BED greater than 49 Gy(12) for radiotherapy-naive brain metastases. The results showed that FSRT with BED > 49 Gy(12) had a lower risk of RN for metastases larger than 20 mm and appeared to be safer than SRS for such lesions.
Article
Oncology
Suchet Taori, Zhishuo Wei, Hansen Deng, Constantinos G. Hadjipanayis, L. Dade Lunsford, Ajay Niranjan
Summary: This study retrospectively analyzed the experience of using Gamma Knife stereotactic radiosurgery in 71 patients with gastroesophageal cancer. The results showed a 12-month local tumor control rate of 90% and rare incidence of adverse radiation effects, indicating a poor prognosis for patients with brain metastases from gastroesophageal cancer.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Article
Clinical Neurology
Georgios Mantziaris, Stylianos Pikis, Zhiyuan Xu, Reed Mullen, Juan Alzate, Kenneth Bernstein, Douglas Kondziolka, Zhishuo Wei, Ajay Niranjan, L. Dade Lunsford, Roman Liscak, Jaromir May, Cheng-chia Lee, Huai-che Yang, Francois-Louis Coupe, David Mathieu, Kimball Sheehan, Darrah Sheehan, Joshua D. Palmer, Haley K. Perlow, Selcuk Peker, Yavuz Samanci, Jennifer Peterson, Daniel M. Trifiletti, Matthew J. Shepard, Shahed Elhamdani, Rodney E. Wegner, Herwin Speckter, Wenceslao Hernandez, Ronald E. Warnick, Jason Sheehan
Summary: This retrospective study showed that stereotactic radiosurgery (SRS) is an effective treatment option for intraventricular metastases (IVMs), with a comparable local control rate to SRS for parenchymal brain metastases. However, careful follow-up is needed to detect leptomeningeal spread and hydrocephalus in patients with IVMs.
Review
Oncology
Raees Tonse, Martin C. Tom, Minesh P. Mehta, Manmeet S. Ahluwalia, Rupesh Kotecha
Summary: In modern times, brain metastasis requires multi-modal management and interdisciplinary care. Traditionally, treatment strategies have focused on local treatments alone due to limited efficacy of cytotoxic chemotherapy. However, with the availability of molecular-based therapies with central nervous system penetration, individualized selection of tailored systemic therapies can now be used alongside local treatments. Moreover, the introduction of immune checkpoint inhibitors has further revolutionized the management of brain metastasis patients.
Article
Clinical Neurology
Adomas Bunevicius, Karen Lavezzo, Leah Shabo, Jesse McClure, Jason P. Sheehan
Summary: The study evaluated the quality of life in patients treated with stereotactic radiosurgery for brain metastases, finding that the quality of life remained largely stable post-treatment. Factors such as the patient's RPA class, upfront whole-brain radiation therapy, and the number of intracranial lesions were identified as independent predictors of post-treatment quality of life deterioration. Additionally, a lower pre-treatment quality of life was associated with shorter survival independently of other clinical and demographic variables.
JOURNAL OF NEUROSURGERY
(2021)
Article
Oncology
Raphael Bodensohn, Anna -Lena Kaempfel, Anne-Laure Boulesteix, Anna Maria Orzelek, Stefanie Corradini, Daniel Felix Fleischmann, Robert Forbrig, Sylvia Garny, Indrawati Hadi, Jan Hofmaier, Giuseppe Minniti, Ulrich Mansmann, Montserrat Pazos Escudero, Niklas Thon, Claus Belka, Maximilian Niyazi
Summary: This prospective nonrandomized controlled trial aimed to compare whole-brain radiotherapy (WBRT) and stereotactic radiosurgery (SRS) in the treatment of multiple brain metastases. Propensity-score matching was performed to compare the efficacy between SRS and historical WBRT control groups. The results showed no significant differences in overall survival and intracranial progression-free survival between the two groups, and no grade III toxicities were observed in the SRS group. The trial did not meet its primary endpoint, and further prospective randomized trials are needed in the era of immunotherapy and targeted therapies.
RADIOTHERAPY AND ONCOLOGY
(2023)
Review
Oncology
Jerome J. Graber, Santosh Kesari
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2018)
Article
Clinical Neurology
R. J. Young, A. Gupta, A. D. Shah, J. J. Graber, A. D. Schweitzer, A. Prager, W. Shi, Z. Zhang, J. Huse, A. M. P. Omuro
AMERICAN JOURNAL OF NEURORADIOLOGY
(2013)
Article
Radiology, Nuclear Medicine & Medical Imaging
Robert J. Young, Ajay Gupta, Akash D. Shah, Jerome J. Graber, Timothy A. Chan, Zhigang Zhang, Weiji Shi, Kathryn Beal, Antonio M. Omuro
Review
Biochemistry & Molecular Biology
Jerome J. Graber, Suhayl Dhib-Jalbut
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
(2014)
Article
Oncology
Jerome J. Graber, Lakshmi Nayak, Lisa M. DeAngelis
JOURNAL OF NEURO-ONCOLOGY
(2012)
Letter
Clinical Neurology
David S. Younger, Jerome Graber, Yoshika Hayakawa-Yano, Salina Parveen, Mayu Frank, Robert B. Darnell
Article
Clinical Neurology
Joanna G. Becker, Gregory M. Pastores, Alessandro Di Rocco, Marissa Ferraris, Jerome J. Graber, Swati Sathe
PARKINSONISM & RELATED DISORDERS
(2013)
Article
Clinical Neurology
A. Gupta, R. J. Young, A. D. Shah, A. D. Schweitzer, J. J. Graber, W. Shi, Z. Zhang, J. Huse, A. M. P. Omuro
CLINICAL NEURORADIOLOGY
(2015)
Review
Clinical Neurology
Alipi V. Bonm, Reed Ritterbusch, Patrick Throckmorton, Jerome J. Graber
JOURNAL OF NEUROIMAGING
(2020)
Letter
Oncology
Jerome J. Graber, Benjamin Plato, Raya Mawad, Daniel J. Moore
LEUKEMIA & LYMPHOMA
(2020)
Review
Clinical Neurology
Boryana M. Eastman, Vyshak A. Venur, Simon S. Lo, Jerome J. Graber
JOURNAL OF NEUROSURGICAL SCIENCES
(2020)
Review
Clinical Neurology
Evan Y. Choi, William A. Gomes, Missak Haigentz, Jerome J. Graber
NEURO-ONCOLOGY PRACTICE
(2016)
Article
Clinical Neurology
Jerome J. Graber, Viviane Tabar, Cameron Brennan, Marc Rosenblum, Lisa M. DeAngelis
INTERDISCIPLINARY NEUROSURGERY-ADVANCED TECHNIQUES AND CASE MANAGEMENT
(2014)
Article
Clinical Neurology
Robert L. Glover, Lauren V. DeNiro, Patrick A. Lasala, Karen M. Weidenheim, Jerome J. Graber, Alexis Boro
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2015)